Lead Product(s) : Pimodivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Janssen to Discontinue Pimodivir Influenza Development Program
Details : Results from pre-planned interim analyses of the Phase 3 pimodivir trial in hospitalised influenza A patients indicate pimodivir in conjunction with the standard of care is unlikely to demonstrate additional benefit in hospitalised influenza A patients c...
Product Name : JNJ-63623872
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 09, 2020
Lead Product(s) : Pimodivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
